A new RAND study uncovers significant differences between healthcare costs paid by privately insured patients and those paid out by Medicare.
A proposed policy calling for hospitals to publicly disclose negotiated prices charged for services is drawing ire from some hospitals and insurance companies.
Asembia offers broad coverage across specialty pharmacy.
Pharmacists are in a unique position to improve orphan drug and precision medicine channels.
Experts offer their thoughts on what the specialty pharmacy industry will look like over the next year.
As the healthcare landscape continues to change at a rapid pace, drug manufacturers need to take a long, hard look at their marketing and commercialization options.
With so many new immunotherapy treatments on the horizon, pharmacists need to understand the ins and outs of immuno-oncology biomarkers to best serve their patients.
The FDA Commissioner says that insurers can help biosimilar adoption by taking short-term financial losses over long-term drug savings. What else should they be doing?
At the 2019 Asembia Specialty Pharmacy Summit, Cardinal Health’s Bruce Feinberg articulates the pros and cons of copay accumulator programs.
OptumRx will expand its drug discounts to employer-sponsored health plans starting next year. Here’s what the move means for healthcare.